Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8428)	1/22/1999 4:19:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Find it!!!. Thank you again, Tharos. Thank you again, George. Message 4967600 I have being trying to get the trial protocol and it was in the sink bowl all the time. Please do no waste the thread legacy. They are two arms of Bpi patients in the study (arms, please stop the legs non-sense that is the market bull who has legs). And one of placebo patients. That's the reason for the season. One needs more than 100 patients for each arm, if one ones to be conservative (parsimoniously agree) then one has to go for more than 300 subjects. Also check the post # 638.

To: aknahow who wrote (8428)	1/22/1999 4:39:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 17367

george, A perfect example of the dangers of subset analysis. From a description of ABTI's previous study: In the upper GI surgery stratum (non-colorectal, n=391), there was a prominent and statistically significant reduction in serious post-operative infections in both Betafectin dose groups versus placebo. The percentage of patients with serious infections decreased 39% in the two treated groups compared to placebo; 46 of 129 (36%) patients in the placebo group experienced serious infection, while 29 of 132 (22%) patients in the 0.5 mg/kg Betafectin group and 28 of 130 (22%) patients in the 1.0 mg/kg Betafectin group experienced serious infection (p=0.01). This key result provided the basis for the ongoing confirmatory trial in upper GI surgery patients. Peter

To: aknahow who wrote (8428)	1/22/1999 5:13:00 PM
From: Cacaito	Respond to of 17367

George, please noticed in the trial Bpi protocol criteria: below 8 Glasgow score do not entry study. Even the lowest score arm patients are significantly ill (shock inminent), and the highest score are very ill (shock). Xoma's chances: 1. no effectiveness in neither group. 2. effective in severely sick patients, not in moderately ill 3. effective in moderately ill, not in severely ill 4. effective in both groups This is a clever design, and if one adds the appropriate number of patients, chances are better for obtaining strog data. The company that gave xoma $25 millions is not unhappy with more subjects in the study.